Glenmark Therapeutics Inc.， USA推出盐酸奥洛他定滴眼液 USP，0.2%（非处方药）-动脉网

Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)

CISION 等信源发布 2025-06-16 21:00



可切换为仅中文







MAHWAH, N.J.

马瓦，新泽西州

，

June 16, 2025

2025年6月16日

/PRNewswire/ -- Glenmark Therapeutics Inc.,

/PRNewswire/ -- 格伦马克治疗学公司，

USA

美国

(Glenmark) is pleased to announce the launch

(Glenmark) 很高兴地宣布推出

of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC); compared to the active ingredient in Pataday®

盐酸奥洛他定眼药水USP，0.2%（非处方药）；与Pataday®中的活性成分相比

Once Daily Relief.

每日一次缓解。

According to Nielsen® syndicated data for the latest 52-week period ending

根据尼尔森®联合数据，截至最近一个52周的时段结束时

May 17, 2025

2025年5月17日

, the Pataday® Once Daily Relief (OTC) market

，Pataday® 每日一次缓解（非处方药）市场

achieved annual sales of approximately

实现了大约年度销售额

$50.0 million

5000万美元

Commenting on the launch,

在发射之际发表评论，

Marc Kikuchi

马克·木村

, President & Business Head,

，总裁兼业务主管，

North America

北美

said

说

, 'We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.2%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.'

“我们很高兴地宣布推出0.2%的奥洛他定眼药水USP，满足了市场对这一类别新供应商日益增长的需求。这一新增产品彰显了我们致力于满足市场需求，并为客户提供高质量的非处方解决方案。”

For product information and how to purchase, please visit:

有关产品信息和购买方式，请访问：

https://glenmarkpharma-us.com/olopatadine-0.2

。

About Glenmark Pharmaceuticals Ltd.

关于格伦马克制药有限公司

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.

格伦马克制药有限公司（BSE：532296）（NSE：GLENMARK）是一家以研发为导向的全球制药公司，业务涵盖品牌药、仿制药和非处方药领域，专注于呼吸系统、皮肤病学和肿瘤学治疗领域。该公司在四大洲拥有11个世界级的生产设施，并在80多个国家开展业务。

Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024. Glenmark's Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in .

Scrip 100 将 Glenmark 列为 2023 年按制药销售额排名的前 100 家生物制药公司之一；而《仿制药公报》则将其列为 2024 年按销售额排名的前 50 家仿制药和生物类似药公司之一。Glenmark 的温室气体 (GHG) 排放减少目标在 2023 年获得了科学基础减碳目标倡议 (SBTi) 的批准，使其成为第二家获此认可的制药公司。

India

印度

to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions. For more information, visit

为实现这一目标。该组织在过去十年中，通过其企业社会责任干预措施影响了超过330万人的生活。欲了解更多信息，请访问

www.glenmarkpharma.com

. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (Glenmark_pharma).

您可以在LinkedIn（Glenmark Pharmaceuticals）和Instagram（Glenmark_pharma）上关注我们。

References

参考文献

Glenmark's Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) is only marketed for the indications listed in Glenmark's approved drug facts label.

Glenmark的盐酸奥洛他定滴眼液USP，0.2%（非处方药）仅用于Glenmark批准的药物说明标签中列出的适应症。

This product is not manufactured or distributed by Alcon Laboratories, Inc., distributor of Pataday® Once Daily Relief, and/or Novartis AG, owner of the registered trademark Pataday®, respectively. [Neither Alcon nor Novartis make or license Glenmark's product.]

本产品并非由奥康实验室有限公司（Alcon Laboratories, Inc.）生产或分销，该公司是Pataday®每日一次缓解剂的分销商，也非诺华公司（Novartis AG）生产或分销，该公司是注册商标Pataday®的所有者。[奥康和诺华均不制造或许可格兰马克的产品。]

Market includes brand and all available therapeutic equivalents. Note: Nielsen syndicated data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications..

市场包括品牌及所有可用的治疗等效品。注意：Glenmark获得的Nielsen联合数据仅适用于所有获批的RLD适应症。Glenmark的产品仅获批用于Glenmark批准标签中列出的适应症，并未针对所有RLD适应症进行销售。

*Nielsen® NIQ Discover; Syndicated Data for Period Ending

*尼尔森® NIQ Discover；截至周期的联合数据

May 17, 2025

2025年5月17日

Logo:

标志：

https://mma.prnewswire.com/media/451507/5371231/PRNE_Glenmark_Logo.jpg

SOURCE Glenmark Pharmaceuticals Ltd

来源：格伦马克制药有限公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻